サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534042

天然痘治療の世界市場

Smallpox Treatment

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
天然痘治療の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

天然痘治療の世界市場は2030年までに7,370万米ドルに達する見込み

2023年に6,550万米ドルと推定された天然痘治療の世界市場は、2030年には7,370万米ドルに達し、分析期間2023-2030年のCAGRは1.7%で成長すると予測されます。本レポートで分析したセグメントの1つである抗ウイルス薬は、CAGR 1.6%を記録し、分析期間終了時には3,250万米ドルに達すると予測されます。予防接種セグメントの成長率は、分析期間中CAGR 2.0％と推定されます。

米国市場は1,780万米ドルと推定、中国はCAGR3.0%で成長すると予測

米国の天然痘治療市場は2023年に1,780万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 3.0%で推移し、2030年には1,350万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と1.5％と予測されています。欧州では、ドイツがCAGR 1.1％で成長すると予測されています。

天然痘治療市場- 主要動向と促進要因のまとめ

天然痘は1980年に根絶が宣言された重篤な感染症であるが、決定的な治療法が存在しないため、その医療管理は主に支持療法に重点が置かれています。生物兵器として使用される可能性が懸念されるため、治療プロトコールでは、ウイルス感染を防ぐため、すべてのかさぶたが剥がれ落ちるまで感染患者を隔離することになっています。FDAが2018年にテコビリマット、2021年にブリンシドフォビルといった医薬品を承認したことで、利用可能な治療選択肢は大きく進歩し、動物実験では有効性が実証され、緊急用プロトコルでは承認されています。FDAは、医薬品開発を促進し、国民の血液供給の安全性を確保することで、天然痘に対する医療対策の利用可能性を確保するという重要な役割を果たしています。ACAM2000、Jynneos、そして治験中のAventis Pasteur Smallpox Vaccineのようなワクチンは、戦略的国家備蓄として極めて重要であり、流行時に配備できるように準備されています。経口剤と静脈注射剤の両方が入手可能なテコビリマットやブリンシドフォビルなどの治療薬も、緊急用リソースの一部です。

数十年前に天然痘が根絶されたにもかかわらず、天然痘の治療や予防措置が採用される背景には、いくつかの要因があります。その第一は、天然痘が生物兵器として使用される可能性のあるバイオテロの脅威が、世界各国の政府の政策やヘルスケア戦略に大きな影響を与えていることです。この潜在的脅威は、ワクチンと抗ウイルス薬の継続的な研究と備蓄を保証しています。医学研究の技術的進歩により、より効果的で安全な天然痘ワクチンや治療が可能になり、その普及が進んでいます。さらに、世界の保健安全保障の取り組みは、潜在的な大流行への備えの重要性を強調し、診断および治療法の選択肢の進歩を後押ししています。公衆衛生政策も重要な役割を果たしており、ワクチンや抗ウイルス剤の戦略的備蓄の維持など、アウトブレイクに対処するための一定のプロトコルが義務付けられています。最後に、感染症対策のための国際協力と資金援助は、天然痘医療対策の準備と利用可能性をさらに支援し、将来起こりうる大流行に対する世界の盾を強化します。

調査対象企業の例（全86件）

  • Bavarian Nordic AS
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Emergex Vaccines
  • EpiVax, Inc.
  • Oncovir, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • SIGA Technologies Inc
  • Tonix Pharmaceuticals Holding Corp.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26630

Global Smallpox Treatment Market to Reach US$73.7 Million by 2030

The global market for Smallpox Treatment estimated at US$65.5 Million in the year 2023, is expected to reach US$73.7 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Antiviral Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$32.5 Million by the end of the analysis period. Growth in the Vaccinations segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$17.8 Million While China is Forecast to Grow at 3.0% CAGR

The Smallpox Treatment market in the U.S. is estimated at US$17.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Smallpox Treatment - Key Trends and Drivers

The medical management of smallpox, a severe infectious disease declared eradicated in 1980, largely focuses on supportive care as no definitive treatment exists. With concerns about its potential use as a bioweapon, the treatment protocol involves isolation of infected patients until all scabs have fallen off to prevent virus transmission. With the FDA's approval of drugs like tecovirimat in 2018 and brincidofovir in 2021, there has been significant advancement in the therapeutic options available, demonstrating effectiveness in animal studies and approved under protocols for emergency use. The FDA plays a critical role in ensuring the availability of medical countermeasures against smallpox through facilitating drug development and ensuring the safety of the nation's blood supply. Vaccines like ACAM2000, Jynneos, and the investigational Aventis Pasteur Smallpox Vaccine are crucial in the Strategic National Stockpile, ready for deployment in case of an outbreak. Treatment drugs such as tecovirimat, available in both oral and intravenous forms, and brincidofovir are part of the emergency resources.

Several factors drive the adoption of smallpox treatments and preventive measures despite the eradication of the disease decades ago. Primarily, the persistent threat of bioterrorism where smallpox could be used as a biological weapon significantly influences government policies and healthcare strategies worldwide. This potential threat ensures continued research into and stockpiling of vaccines and antiviral medications. Technological advances in medical research allow for more effective and safer smallpox vaccines and treatments, increasing their adoption. Furthermore, global health security initiatives emphasize the importance of preparedness for potential outbreaks, pushing for advancements in diagnostic and therapeutic options. Public health policies also play a crucial role; they mandate certain protocols for handling outbreaks, which include the maintenance of strategic reserves of vaccines and antivirals. Finally, international cooperation and funding for infectious disease control further support the readiness and availability of smallpox medical countermeasures, reinforcing a global shield against possible future outbreaks.

Select Competitors (Total 86 Featured) -

  • Bavarian Nordic AS
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Emergex Vaccines
  • EpiVax, Inc.
  • Oncovir, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • SIGA Technologies Inc
  • Tonix Pharmaceuticals Holding Corp.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Smallpox Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Health Security Initiatives Drive Demand for Smallpox Treatments
    • Technological Advancements in Vaccine Storage and Stability
    • Emergence of Drug-Resistant Smallpox Strains Spurs Innovation
    • Enhancements in Vaccine Delivery Methods Propel Market Growth
    • Rise in Bioterrorism Threats Catalyzing Smallpox Preparedness
    • Collaborations between Governments and Pharmaceutical Companies
    • Advancements in Diagnostic Techniques Boosting Treatment Efficacy
    • Global Health Organizations' Focus on Eradication Programs
    • Funding Increases for Infectious Disease Research and Development
    • Integration of AI in Epidemiological Predictions and Vaccine Development
    • Regulatory Fast-Tracking of Critical Smallpox Medications
    • Ethical and Legal Challenges in Vaccine Deployment
    • Global Health Organizations Focus on Eradication Programs
    • Public Awareness and Education Campaigns Impact on Treatment Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Smallpox Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Smallpox Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Vaccinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Smallpox Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Smallpox Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Smallpox Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Smallpox Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION